NKTR vs VRTX · rev $21.0M vs P/E 30, rev $3.33B
Nektar Therapeutics (NKTR) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported NKTR revenue for 2026-06-30 was $21.0M. Net income was -$85.5M. Revenue was up 93.3% from 2026-03-31 to 2026-06-30. NKTR currently screens at market cap $307.2M.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
NKTR currently screens at market cap $307.2M. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the NKTR and VRTX stock pages for the full models.
Not investment advice.